The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine
Abstract
Nanomedicine is a promising strategy for improving clinical outcomes for cancer therapies, by improving drug efficacy through enhanced delivery to disease sites. It is of importance for ultimate clinical success to consider the contributing factors to achieving this goal, such as size, chemistry, and functionality of nanoparticle delivery systems, and how these parameters influence tumor localization and uptake. This Topical Review will first discuss the evolution and progress of nanoparticles for cancer drug delivery and the current challenges that remain to be addressed. Strategies for overcoming the limitations of passive targeting through active targeting approaches, and the current state of such nanomedicines in the clinic will be highlighted. Finally, novel approaches toward the design of active targeted nanoparticles building on our growing understanding of nanobio interactions are considered, in order to shed light on future design considerations for accelerating clinical translation of nanomedicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,136
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
van Vlerken, L. E., Vyas, T. K., & Amiji, M. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9284-6 · Cited by 645
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Transferrin receptor 1 in cancer: a new sight for cancer therapy.
Shen, Y., Li, X., Dong, D., Zhang, B., Xue, Y., & Shang, P. (2018) · Europe PMC (PubMed Central) · Cited by 483
Yamamoto, Y., Nagasaki, Y., Kato, Y., Sugiyama, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00451-5 · Cited by 442
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Fang, C., Shi, B., Pei, Y.-Y., Hong, M.-H., Wu, J., & Chen, H.-Z. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.08.002 · Cited by 424
Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles
Ruoslahti, E. (2012) · Advanced Materials · doi:10.1002/adma.201200454 · Cited by 419
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Hu, Y., Xie, J., Tong, Y. W., & Wang, C.-H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.11.028 · Cited by 351
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Autio, K. A., Dreicer, R., Anderson, J., Garcia, J. A., Alva, A., Hart, L. L., Milowsky, M. I., Posadas, E. M., Ryan, C. J., Graf, R. P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2168 · Cited by 275
Crist, R. M., Grossman, J. H., Patri, A. K., Stern, S. T., Dobrovolskaia, M. A., Adiseshaiah, P. P., Clogston, J. D., & McNeil, S. E. (2013) · Integrative Biology · doi:10.1039/c2ib20117h · Cited by 265
Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics
Liang, R., Wei, M., Evans, D. G., & Duan, X. (2014) · Chem. Commun. · doi:10.1039/c4cc03118k · Cited by 262
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253
Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications
Englert, C., Brendel, J. C., Majdanski, T. C., Yildirim, T., Schubert, S., Gottschaldt, M., Windhab, N., & Schubert, U. S. (2018) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2018.07.005 · Cited by 247
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
Xu, L., Huang, C., Huang, W., Tang, W., Rait, A. S., Yin, Y. Z., Cruz, I., Xiang, L., Pirollo, K. F., & Chang, E. H. (2002) · PubMed · Cited by 243
Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress
Marcucci, F., & Lefoulon, F. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02988-x · Cited by 236
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 236
Targeting of albumin-embedded paclitaxel nanoparticles to tumors
Karmali, P. P., Kotamraju, V. R., Kastantin, M., Black, M., Missirlis, D., Tirrell, M., & Ruoslahti, E. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.07.007 · Cited by 234
Sun, X., Rossin, R., Turner, J. L., Becker, M. L., Joralemon, M. J., Welch, M. J., & Wooley, K. L. (2005) · Biomacromolecules · doi:10.1021/bm050260e · Cited by 223
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Ashton, S., Song, Y. H., Nolan, J., Cadogan, E., Murray, J., Odedra, R., Foster, J., Hall, P. A., Low, S., Taylor, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2355 · Cited by 218
Bertholon, I., Vauthier, C., & Labarre, D. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0069-0 · Cited by 169
Vaidya, A. M., Sun, Z., Ayat, N., Schilb, A., Liu, X., Jiang, H., Sun, D., Scheidt, J., Qian, V., He, S., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00028 · Cited by 169
Miller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J. G., Wickham, T. J., Molnar, I., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2385-z · Cited by 168
Polymer therapeutics: Top 10 selling pharmaceuticals — What next?
Duncan, R. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.001 · Cited by 161
Arpicco, S., Milla, P., Stella, B., & Dosio, F. (2014) · Molecules · doi:10.3390/molecules19033193 · Cited by 150
Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44
Spadea, A., Rosa, J. M. R. D. L., Tirella, A., Ashford, M. B., Williams, K. J., Stratford, I. J., Tirelli, N., & Mehibel, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00083 · Cited by 147
Targeting the Delivery of Glycan-Based Paclitaxel Prodrugs to Cancer Cells via Glucose Transporters
Lin, Y.-S., Tungpradit, R., Sinchaikul, S., An, F.-M., Liu, D.-Z., Phutrakul, S., & Chen, S.-T. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006257 · Cited by 120
Pirollo, K. F., Nemunaitis, J. J., Leung, P. K., Nunan, R., Adams, J., & Chang, E. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.135 · Cited by 118
Clinical Experience With Denileukin Diftitox (ONTAK)
Foss, F. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.017 · Cited by 116
Camp, E. R., Wang, C., Little, E. C., Watson, P. M., Pirollo, K. F., Rait, A. S., Cole, D. J., Chang, E. H., & Watson, D. K. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.9 · Cited by 115
Sikorski, A. F., Toporkiewicz, M., Meissner, J. M., Matusewicz, L., & Czogalla, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s74514 · Cited by 112
Maruyama, K. (2002) · Bioscience Reports · doi:10.1023/a:1020138622686 · Cited by 109
Accomasso, L., Cristallini, C., & Giachino, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00228 · Cited by 103
Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
Elsässer‐Beile, U., Bühler, P., & Wolf, P. (2009) · Current Drug Targets · doi:10.2174/138945009787354601 · Cited by 91
Musyanovych, A., Dausend, J., Dass, M., Walther, P., Mailänder, V., & Landfester, K. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.07.033 · Cited by 88
Gao, Y., Zhou, Y., Zhao, L., Zhang, C., Li, Y., Li, J., Li, X., & Liu, Y. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.05.021 · Cited by 81
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Blackwelder, W. C., Gordon, E. M., & Hall, F. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.228 · Cited by 81
Rexin-G, a targeted genetic medicine for cancer
Gordon, E. M., & Hall, F. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481666 · Cited by 79
Pearce, A. K., Simpson, J. D., Fletcher, N. L., Houston, Z. H., Fuchs, A. V., Russell, P. J., Whittaker, A. K., & Thurecht, K. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.004 · Cited by 79
Self-citationStimuli‐Responsive Prodrug Chemistries for Drug Delivery
Taresco, V., Alexander, C., Singh, N., & Pearce, A. K. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800030 · Cited by 79
Self-citationThe Role of Nanomaterials in Translational Medicine
Lavik, E., & von Recum, H. A. (2011) · ACS Nano · doi:10.1021/nn201371a · Cited by 78
Hamaguchi, T., Matsumura, Y., Nakanishi, Y., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Niki, H., Hosokawa, S., Tagawa, T., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02495.x · Cited by 74
Wei, T., Zhang, J., Zeng, X., Liu, D. X., Liu, G., Zhu, X., Liu, Y., Yu, Q., Huang, L., & Mei, L. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400751 · Cited by 74
Antibody-Targeted Nanoparticles for Cancer Treatment
Carter, T. J., Mulholland, P. J., & Chester, K. A. (2016) · Immunotherapy · doi:10.2217/imt.16.11 · Cited by 73
Mansur, A. A. P., Carvalho, S. M., Lobato, Z. I. P., Leite, M. F., Silva‐Cunha, A., & Mansur, H. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00208 · Cited by 72
Lee, S. Y., & Cho, H. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b01449 · Cited by 72
Singh, R., Nörret, M., House, M. J., Galabura, Y., Bradshaw, M., Ho, D., Woodward, R. C., Pierre, T. G. S., Luzinov, I. A., Smith, N. M., et al. (2015) · Small · doi:10.1002/smll.201502730 · Cited by 71
Human Tumor Xenografts: The Good, the Bad, and the Ugly
Morgan, R. A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.73 · Cited by 69
Dormont, F., Rouquette, M., Mahatsekake, C., Gobeaux, F., Peramo, A., Brusini, R., Calet, S., Testard, F., Lepêtre‐Mouelhi, S., Desmaële, D., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.040 · Cited by 66
Chawla, S. P., Bruckner, H. W., Morse, M. A., Assudani, N., Hall, F. L., & Gordon, E. M. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.005 · Cited by 60
Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs
van den Brand, D., Massuger, L. F. A. G., Brock, R. E., & Verdurmen, W. P. R. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00699 · Cited by 55
Pharmacokinetics and biodistribution of the nanoparticles
Raza, K., Kumar, P., Kumar, N., & Malik, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100557-6.00009-2 · Cited by 52
Sun, B., Deng, C., Meng, F., Zhang, J., & Zhong, Z. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.08.048 · Cited by 48
Harnessing RNAi nanomedicine for precision therapy
Peer, D. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-5 · Cited by 35
Bartheldyová, E., Effenberg, R., Mašek, J., Procházka, L., Knötigová, P. T., Kulich, P., Hubatka, F., Velínská, K., Bezděková, J., Zouharová, D., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00311 · Cited by 34
Patil, S. P., Kim, S., Jadhav, J. R., Lee, J.-H., Jeon, E. M., Kim, K., & Kim, B. H. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500249g · Cited by 17
Jain, M. M., Patil, S., Pathak, A. B., Deshmukh, C. D., Bhatt, N., Babu, K. G., Haritha, C., Bondarde, S. A., Digumarti, R., Bajpai, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.1069 · Cited by 4
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Spotlight on Luminescence Thermometry: Basics, Challenges, and Cutting‐Edge Applications
Brites, C. D. S., Marin, R., Suta, M., Carneiro Neto, A. N., Ximendes, E., Jaque, D., & Carlos, L. D. (2023) · Advanced Materials · doi:10.1002/adma.202302749 · Cited by 464
Magnetic nanoparticles in biomedical applications: A review
Materón, E. M., Miyazaki, C. M., Carr, O., Joshi, N., Picciani, P. H. S., Dalmaschio, C. J., Davis, F., & Shimizu, F. M. (2021) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2021.100163 · Cited by 456
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 433
Metadata
- Authors
- Pearce, A. K., & O’Reilly, R. K.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-08-23
- Volume
- 30
- Issue
- 9
- Pages
- 2300-2311
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2969822417
- Cited by
- 275
- References
- 95
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.